How to Check for Breast Cancer: What Actually Works

Checking for breast cancer isn't a single test. It's a mix of imaging, physical exams, and sometimes genetic testing, each with its own job and its own track record. Some methods have decades of trial evidence behind them. Others, like breast self-exams, turn out to work less well than many people assume. Understanding what each method can and can't do helps make sense of screening recommendations, rather than treating them as one universal rule.

Mammography: The Method With the Strongest Track Record

Mammography, an X-ray picture of the breast, remains the backbone of breast cancer screening programs. Large systematic reviews pooling randomized trials and population data have found that regular mammography reduces deaths from breast cancer in women of average risk, with the clearest benefit seen between ages 40 and 74. That reduction isn't dramatic for any one person, but across a screened population it adds up to meaningfully fewer deaths over time.

Based on that balance of benefit and harm, current guidance recommends mammography on a regular schedule starting around age 40 for women at average risk, continuing into the mid-seventies. Different countries and organizations set the exact ages and intervals somewhat differently, reflecting the same trade-off weighed with slightly different assumptions. None of this is a fixed rule for every individual; the right starting point and frequency depends on personal risk and is worth working out with a healthcare provider.

Self-Exams and Clinical Exams: Useful for Awareness, Not a Substitute

Many people grew up being told to check their own breasts regularly for lumps. It's a reasonable habit for noticing changes, but the evidence that it saves lives is thin. A large randomized trial conducted in Shanghai followed hundreds of thousands of women taught a structured self-exam technique and found no reduction in breast cancer deaths compared with women who weren't taught it. A later Cochrane review reached the same conclusion, and added that structured self-exam increased the number of benign lumps that were biopsied, meaning more procedures without a matching survival benefit.

Clinical breast exam, performed by a doctor or nurse's hands rather than a machine, fares similarly. The same Cochrane review found insufficient evidence that it reduces breast cancer mortality on its own. None of this means noticing a change in your own body is pointless; being familiar with how your breasts normally look and feel can still prompt a useful conversation with a doctor. It simply means neither self-exam nor clinical exam has been shown to replace what imaging-based screening does.

The Cost Side of Screening: Overdiagnosis and False Positives

Screening isn't free of downsides. Comparing cancer rates before and after mammography became widespread, one analysis by researcher H. Gilbert Welch and a colleague estimated that a meaningful share of cancers found through screening would never have grown large enough to cause symptoms or death if left undetected. That phenomenon is called overdiagnosis. Because there's no reliable way to tell, at the time of diagnosis, which detected cancer belongs to that group, people found to have one are generally treated anyway, which means surgery, radiation, or other treatment for some who would have been fine without it.

False positives are a related, more immediate harm: a mammogram result that looks suspicious but turns out, after further imaging or biopsy, not to be cancer. These don't change outcomes, but they do create anxiety and extra procedures. Weighing these harms against the mortality benefit is exactly what guideline bodies do when setting recommended ages and intervals. Screening isn't simply good or bad; the balance shifts with age, individual risk, and how often testing happens.

When Dense Breast Tissue Complicates the Picture

Breasts aren't uniform. Some contain mostly fatty tissue, while others have more glandular and fibrous tissue packed in, a difference called breast density. Denser tissue shows up white on a mammogram, the same shade as many tumors, which makes abnormalities harder to spot. Think of it like trying to find a snowball lying in a field of snow. Research comparing cancers found at routine screening with those that turned up between screening visits has shown mammography is less sensitive in women with denser breasts, meaning more cancers in this group are missed on the initial scan and sometimes only found later, at a more advanced stage.

Breast density isn't just a technical nuisance for imaging, though. It's also, independently, a risk factor for developing breast cancer in the first place. That combination, tissue that's both harder to screen and linked to higher risk, is one reason some women with dense breasts are offered supplemental imaging alongside standard mammography.

Genetic Risk and the Case for Personalized Screening

For most people, breast cancer risk rises gradually with age. For a minority, it's shaped much more strongly by inherited genetics. Mutations in two genes, BRCA1 and BRCA2, which normally help repair damaged DNA, substantially raise lifetime risk of both breast and ovarian cancer when inherited in a faulty form. Family-based research going back decades first established that this risk runs in families along recognizable inheritance patterns, and large cohort studies following known mutation carriers have since quantified just how much that risk rises compared with the general population.

Because of this, current guidance recommends that people with certain personal or family history patterns, such as multiple relatives with breast or ovarian cancer, or a diagnosis at an unusually young age, be referred for genetic risk assessment and counseling before deciding whether to pursue testing. This isn't a call to test everyone. It's a filter meant to identify the relatively small group of people for whom the information would meaningfully change their care.

For women confirmed to carry one of these mutations, or otherwise known to be at high familial risk, mammography alone tends to underperform. Research led by Christiane Kuhl, later supported by a large randomized trial, found that adding MRI, an imaging technique that uses magnetic fields rather than X-rays, to mammography detects more cancers in this high-risk group than mammography alone. MRI isn't offered as a routine first-line test for average-risk women. Its added sensitivity comes with more false positives too, which is why it's reserved for people whose elevated risk justifies that trade-off.

Matching the Method to the Person

No single check captures everything screening is meant to do. Mammography remains the method with the clearest mortality benefit for average-risk adults. Self-exams and clinical exams can build body awareness, but shouldn't be relied on as a substitute. Dense breast tissue and inherited genetic risk are two separate, sometimes overlapping, reasons some people are offered more than the standard approach.

None of this adds up to one schedule that fits everyone. The right age to start, how often to return, and whether to add MRI or pursue genetic counseling all depend on personal and family history. Those decisions are worth working through directly with a healthcare provider, rather than inferring from a general rule.